Developing an Edema Clinician-Reported Outcome Measure for Nephrotic Syndrome

Glomerular Dis. 2023 Jun 12;3(1):132-139. doi: 10.1159/000531505. eCollection 2023 Jan-Dec.

Abstract

Introduction: Edema is a common manifestation of proteinuric kidney diseases, but there is no consensus approach for reliably evaluating edema. The objective of this study was to develop an edema clinician-reported outcome measure for use in patients with nephrotic syndrome.

Methods: A literature review was conducted to assess existing clinician-rated measures of edema. Clinical experts were recruited from internal medicine, nephrology, and pediatric nephrology practices to participate in concept elicitation using semi-structured interviews and cognitive debriefing. Qualitative analysis methods were used to collate expert input and inform measurement development. In addition, training and assessment modules were developed using an iterative process that also utilized expert input and cognitive debriefing to ensure interrater reliability.

Results: While several clinician-rated measures of edema have been proposed, our literature review did not identify any studies to support the reliability or validity of these measures. Fourteen clinician experts participated in the concept elicitation interviews, and twelve participated in cognitive debriefing. A clinician-reported outcome measure for edema was developed. The measure assesses edema severity in multiple individual body parts. An online training module and assessment tool were generated and refined using additional clinician input and investigative team expertise.

Conclusion: The Edema ClinRO (V1) measure is developed specifically to measure edema in nephrotic syndrome. The tool assesses edema across multiple body parts, and it includes a training module to ensure standardized administration across raters. Future examination of this measure is ongoing to establish its reliability and validity.

Keywords: ClinRO; Clinical outcomes assessment; Focal segmental glomerulosclerosis; Membranous nephropathy; Minimal change disease; Swelling.

Grants and funding

Funding for the study was provided by a grant from Goldfinch Bio through the University of Michigan for the design and conduct of this study. Goldfinch Bio scientists were partners in the study design and are coauthors of this publication.